Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA

ARUP test directory entry for preferred ANA IFA screening. States ANA lacks diagnostic specificity, lists reportable nuclear and cytoplasmic patterns with endpoint titers to 1:2560, and notes negatives do not exclude SARD. Candidate notes: Preferred ANA screening test for systemic autoimmune rheumatic disease per ordering recommendation. IFA on HEp-2 with IgG conjugate at screening dilution 1:80; reference interval less than 1:80. Nuclear patterns: centromere, homogeneous, nuclear dots, nucleolar, or speckled. Cytoplasmic patterns: reticular/AMA, discrete/GW body-like, polar/Golgi-like, cytoplasmic speckled, or rods and rings. All positive patterns reported to endpoint titers (1:2560); mitotic patterns not reported. Positive ANA requires confirmation by more specific serologic tests; negatives do not necessarily rule out SARD. Limits noted in the record: Assay-specific reporting conventions (e.g., mitotic patterns not reported). A positive ANA is not a diagnosis. Claims in this record are not verified.

A positive ANA is not a diagnosis. Claims in this record are not verified.

source